BioSempra NAD+ - 60 Capsules

This randomized, double-blind, placebo-controlled crossover trial (n=30, aged 55–79 years) administered 1000 mg/day of NR for 6 weeks. NR supplementation elevated blood cellular NAD+ concentrations by approximately 60% compared to placebo, and also produced a nearly fivefold increase in NAAD — a sensitive biomarker of enhanced NAD+ metabolism. No serious adverse events occurred, and all standard clinical laboratory markers remained within normal ranges. Exploratory analyses suggested a trend toward reduced systolic blood pressure (approximately 9 mmHg) and reduced aortic stiffness in participants with above-normal baseline blood pressure, identifying cardiovascular function as a priority endpoint for future larger-scale trials.

This 21-day, randomized, double-blind, placebo-controlled crossover trial (n=12 men, median age 75 years) administered 1000 mg/day of NR and confirmed that oral NR is bioavailable to human skeletal muscle — a previously open question. NR produced a twofold increase in the muscle NAD+ metabolome marker NAAD and a greater than twofold increase in blood NAD+ levels, alongside a fivefold elevation in NAM methylation clearance products, indicating substantial NAD+ pathway activation. Notably, NR significantly reduced circulating levels of pro-inflammatory cytokines IL-2, IL-5, IL-6, and TNF-α — suggesting meaningful anti-inflammatory effects relevant to aging. No changes in mitochondrial bioenergetics, grip strength, or cardiometabolic parameters were observed after 21 days, suggesting that functional muscle benefits may require longer intervention durations or populations with greater baseline NAD+ deficiency.

This phase 2 RCT (n=46) tested isoquercetin — the orally bioavailable glucoside form of quercetin — at 1000 mg/day for 28–35 days in adults with sickle cell disease. While the primary endpoint (reduction in plasma P-selectin, a platelet activation marker) was not met, the trial demonstrated that isoquercetin significantly reduced whole-blood coagulability, attenuated collagen-induced platelet aggregation, inhibited plasma protein disulfide isomerase reductase activity (a key procoagulant regulator), and suppressed inducible tissue factor gene expression in peripheral blood mononuclear cells. The compound was safe, well-tolerated, and produced no off-target bleeding — confirming quercetin's anti-thromboinflammatory biological activity in humans, while also indicating that higher doses and longer treatment durations may be needed to demonstrate significant primary endpoint effects.

This 52-week, phase II RCT (n=119) tested escalating doses of synthetic resveratrol (up to 2000 mg/day) in adults with mild-to-moderate Alzheimer's disease. Despite the challenging bioavailability of oral resveratrol, the compound was detectable in cerebrospinal fluid and was confirmed safe and well-tolerated at high doses. Notably, resveratrol stabilized cerebrospinal fluid and plasma levels of amyloid-β40 — a key Alzheimer's pathology marker — which declined significantly in the placebo group; additionally, resveratrol reduced CSF matrix metalloproteinase-9 by approximately 50%, suggesting preserved blood-brain barrier integrity and reduced neuroinflammation. While no statistically significant effects were seen on cognitive outcome measures, the study established key proof-of-concept regarding resveratrol's mechanistic engagement with SIRT1-linked aging pathways and its central nervous system anti-inflammatory activity.